Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
J Nucl Med. 2017 Aug;58(8):1330-1333. doi: 10.2967/jnumed.116.188250. Epub 2017 Feb 9.
The methylguanidine derivative C-GMOM (C-labeled -(2-chloro-3-thiomethylphenyl)-'-(3-methoxyphenyl)-'-methylguanidine) has been used successfully to quantify -methyl-d-aspartate (NMDA) receptor binding in humans. The purpose of the present study was to estimate the C-GMOM radiation dose in healthy humans. After C-GMOM injection, 3 female and 2 male subjects underwent 10 consecutive whole-body PET scans in approximately 77 min. Seven source organs were defined manually, scaled to a sex-specific reference, and residence times were calculated for input into OLINDA/EXM software. Accepted tissue-weighting factors were used to calculate the effective dose. The mean absorbed radiation doses in source organs ranged from 7.7 μGy·MBq in the brain to 12.7 μGy·MBq in the spleen. The effective dose (±SD) was 4.5 ± 0.5 μSv·MBq The effective dose of C-GMOM is at the lower end of the range seen for other C-labeled ligands, allowing for serial PET scanning in a single subject.
甲胍衍生物 C-GMOM（C 标记的 -（2-氯-3-硫甲基苯基）-' -（3-甲氧基苯基）-' -甲基胍）已成功用于定量人类中的 -甲基-D-天冬氨酸（NMDA）受体结合。本研究的目的是估计健康人体中的 C-GMOM 辐射剂量。C-GMOM 注射后，3 名女性和 2 名男性受试者在大约 77 分钟内进行了 10 次连续的全身 PET 扫描。手动定义了 7 个源器官，按性别特异性参考进行了缩放，并计算了停留时间以输入 OLINDA/EXM 软件。接受的组织加权因子用于计算有效剂量。源器官的平均吸收辐射剂量范围从大脑中的 7.7 μGy·MBq 到脾脏中的 12.7 μGy·MBq。有效剂量（±SD）为 4.5 ± 0.5 μSv·MBq C-GMOM 的有效剂量处于其他 C 标记配体所见范围的低端，允许在单个受试者中进行连续 PET 扫描。
